Product Information
PERPHENAZINE 8 MG TABLET is a generic product labeled by Actavis Pharma, Inc., priced at $0.1354 per EA under NDC 00591410301. Its NADAC has been published 477 times since Aug 16, 2017.
FDA first approved this application on Oct 17, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
8 mg/1
Manufacturer
Actavis Pharma, Inc.NDC
00591410301
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
PERPHENAZINEApproval Type
Generic (ANDA)
FDA Application
ANDA207582FDA Approved
10/17/2016
TE Code
AB
On Market Since
5/30/2017
Pharmacological Classes
Price Statistics
The NADAC for PERPHENAZINE 8 MG TABLET has been published 477 times since Aug 16, 2017, and over the history we have for it it has declined 90.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1354 per EA |
|---|---|
| All-time high | $1.3478 (Aug 16, 2017) |
| All-time low | $0.1354 (Sep 23, 2026) |
| 52-week high | $0.2472 |
| 52-week low | $0.1354 |
| Median price | $0.4355 |
| Average price | $0.4615 |
| Largest weekly change | +51.6% (Nov 22, 2023) |
| Weeks tracked | 477 |
| Tracking since | Aug 16, 2017 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Actavis Pharma, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Perphenazine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Phenothiazine class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PERPHENAZINE 8 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for PERPHENAZINE 8 MG TABLET, manufactured by Actavis Pharma, Inc., is $0.1354 per EA (NDC 00591410301), effective Sep 30, 2026.
How has the price of PERPHENAZINE 8 MG TABLET changed over time?
Over the history we have for it, the NADAC for PERPHENAZINE 8 MG TABLET has declined 90.0%. It has been tracked across 477 weekly CMS publications since Aug 16, 2017.
What are the highest and lowest recorded NADAC prices for PERPHENAZINE 8 MG TABLET?
Since Aug 16, 2017, the NADAC for PERPHENAZINE 8 MG TABLET has ranged from a low of $0.1354 (Sep 23, 2026) to a high of $1.3478 (Aug 16, 2017), with a median of $0.4355 per EA.
Are there cheaper alternatives to PERPHENAZINE 8 MG TABLET?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as PERPHENAZINE 8 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures PERPHENAZINE 8 MG TABLET?
PERPHENAZINE 8 MG TABLET (NDC 00591410301) is labeled by Actavis Pharma, Inc., and CMS classifies it as a generic product.